Matches in DBpedia 2014 for { <http://dbpedia.org/resource/BAY_73-6691> ?p ?o. }
Showing items 1 to 42 of
42
with 100 items per page.
- BAY_73-6691 abstract "BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors. Consequently selective PDE9A inhibitors were predicted to prolong intracellular responses to glutamate and enhance glutamate signalling, and since this process is known to be involved in learning and memory, PDE9A inhibitors should have a nootropic effect and may be useful in the treatment of Alzheimer's.Animal studies have confirmed these expectations, and BAY 73-6691 has been shown to improve learning and memory in rats. As the first selective PDE9A inhibitor to be developed, it is also widely used in research into the function of this enzyme subtype. However pre-clinical research is at an early stage and it is not yet known whether BAY 73-6691 will prove suitable to progress to human trials, or if it will remain merely a laboratory research tool.".
- BAY_73-6691 casNumber "794568-92-6".
- BAY_73-6691 iupacName "1-(2-chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one".
- BAY_73-6691 pubchem "16078952".
- BAY_73-6691 thumbnail BAY73-6691_structure.png?width=300.
- BAY_73-6691 wikiPageID "20617726".
- BAY_73-6691 wikiPageRevisionID "519744152".
- BAY_73-6691 c "15".
- BAY_73-6691 casNumber "794568".
- BAY_73-6691 chembl "1513993".
- BAY_73-6691 chemspiderid "21171546".
- BAY_73-6691 cl "1".
- BAY_73-6691 f "3".
- BAY_73-6691 h "12".
- BAY_73-6691 hasPhotoCollection BAY_73-6691.
- BAY_73-6691 inchi "1".
- BAY_73-6691 inchikey "FFPXPXOAFQCNBS-MRVPVSSYBD".
- BAY_73-6691 iupacName "1".
- BAY_73-6691 molecularWeight "356.73".
- BAY_73-6691 n "4".
- BAY_73-6691 o "1".
- BAY_73-6691 pubchem "16078952".
- BAY_73-6691 smiles "C[C@H]CF".
- BAY_73-6691 stdinchi "1".
- BAY_73-6691 stdinchikey "FFPXPXOAFQCNBS-MRVPVSSYSA-N".
- BAY_73-6691 verifiedrevid "461349234".
- BAY_73-6691 subject Category:Lactams.
- BAY_73-6691 subject Category:Organochlorides.
- BAY_73-6691 subject Category:Organofluorides.
- BAY_73-6691 subject Category:Phosphodiesterase_inhibitors.
- BAY_73-6691 subject Category:Pyrazolopyrimidines.
- BAY_73-6691 type Drug.
- BAY_73-6691 type DrugProduct.
- BAY_73-6691 type FunctionalSubstance.
- BAY_73-6691 comment "BAY 73-6691 is a drug developed by Bayer for the treatment of Alzheimer's disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors.".
- BAY_73-6691 label "BAY 73-6691".
- BAY_73-6691 sameAs m.05202cz.
- BAY_73-6691 sameAs Q4834702.
- BAY_73-6691 sameAs Q4834702.
- BAY_73-6691 wasDerivedFrom BAY_73-6691?oldid=519744152.
- BAY_73-6691 depiction BAY73-6691_structure.png.
- BAY_73-6691 isPrimaryTopicOf BAY_73-6691.